Ceftobiprole Activity When Tested Against Contemporary Bacteria Causing Bloodstream Infections in the US (2016)
Background. Ceftobiprole medocaril (prodrug of ceftobiprole) is an advanced cephalosporin, approved for adults in multiple European countries for the treatment of hospital-acquired pneumonia (excluding ventilator-associated pneumonia) or community-acquired pneumonia. It is not approved in the US; however, it has achieved qualified infectious disease product status and two phase 3 studies supported by BARDA are planned to begin in the US in 2017.
Methods. CZA and C/T demonstrated poor in vitro activity vs. the isolates. The in vitro activity of MXF was approximately 4 fold more potent than ciprofloxacin. TGC was marginally more active in vitro than doxycycline.
development for the treatment of invasive candidiasis. This study evaluated the in vitro antifungal activity of SCY-078 against a collection of clinical C. parapsilosis isolates.
Methods. Retrospective analysis of data from 7 independent studies evaluating the activity of SCY-078 is presented. Data were available for 206 C. parapsilosis isolates collected between 2008 and 2015 in the US and EU. The collection included 186 wild-type isolates as well as 14 azole-resistant, and 6 echinocandin-resistant isolates. Minimum inhibitory concentrations (MIC) were determined according to the CLSI M27-A3 and EUCAST E.DEF 7.3 guidelines. Comparator compounds varied across studies and included fluconazole, micafungin (MCF), caspofungin (CSP), and anidulafungin (ANI). MIC 50 and MIC 90 values were defined as the concentrations inhibiting growth of 50% and 90% of isolates, respectively. Echinocandin and azole resistance were determined based on CLSI M27-A4 guidelines.
Results. The MIC 50 values obtained for SCY-078 against the wild-type C. parapsilosis isolates across the 7 studies ranged from 0.25 to 1 μg/mL and the MIC 90 values ranged from 0.25 -2 µg/mL. Among the echinocandins, MIC 90 values ranged from 0.5 to 2 µg/mL (CSP), 1 to 4 µg/mL (MCF) and 2 to 4 µg/mL (ANI). SCY-078 was active against the 14 azole-resistant isolates (MIC ranging from 0.25 to 2 µg/mL). Similar activity was observed across the 6 echinocandin-resistant isolates with MIC values for SCY-078 ranging from 0.25 to 1 µg/mL. Among the 4 most recent studies in the US and EU (2013-2015) C. parapsilosis isolates represented 14 -20% of the Candidaisolates; rates were similar in the EU and US.
Conclusion. SCY-078 demonstrated potent activity against C. parapsilosis clinical isolates. Notably, SCY-078 was effective against all the echinocandin and azole resistant C. parapsilosis isolates tested. Methods. A total of 424 organisms recovered from patients with a diagnosis of bacterial endocarditis at US and EU sites during the SENTRY Antimicrobial Surveillance Program (2008 Program ( -2016 were included (see Table) . Isolates were identified by standard biochemical algorithms and MALDI-TOF. Susceptibility (S) testing was performed by CLSI methods, and MICs were interpreted per CLSI and/or EUCAST criteria.
Results. Among the 424 isolates, 212 (50.0%) were S. aureus (SA; 31.6% methicillin-resistant [MRSA]), 47 (11.1%) were coagulase-negative staphylococci (CoNS), 81 (19.1%) were E. faecalis (EFC), 21 (5.0%) were E. faecium (EFM), 24 (5.7%) were BHS, and 39 (9.2%) were viridans group streptococci (VGS). ORI had similar MIC 90 values (0.06 µg/mL) against SA and CoNS, inhibiting 98.8% of these isolates at ≤0.12 µg/mL. ORI MIC 50 values were 8-to 32-fold lower than those for vancomycin (VAN), daptomycin (DAP), and ceftaroline (CPT) against staphylococci. ORI showed MICs against EFM (MIC 50/90 , 0.008/0.03 µg/mL) that were 2-fold lower than against EFC (MIC 50/90 , 0.015/0.03 µg/mL; 97.5%S against all or 100%S against indicated VAN-S isolates) . ORI inhibited 98.0% of all enterococci, including VAN-resistant isolates at ≤0.12 µg/mL. VAN, DAP, ampicillin (MIC 50/90 , ≤1/2 µg/mL), and linezolid (LZD) (MIC 50/90 , 1/2 µg/ mL) were similarly active against EFC, while DAP and LZD had coverage (100.0%S) against EFM. Overall, BHS were highly S to all agents tested, except for erythromycin (70.8%S) and tetracycline (43.5%S). ORI was the most active agent (MIC 90 , 0.12 µg/ mL) tested against VGS.
Conclusion. ORI showed potent in vitro activity against isolates recovered from patients with endocarditis in US and EU sites. The data presented here warrant further investigations to determine whether ORI has a role for treating endocarditis.
